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Pulmonary nodules are a frequent incidental finding on computed tomography (CT) imaging.
This study sought to investigate the prevalence and radiological outcomes of lung nodules in
patients with alpha 1-antitrypsin deficiency (AATD), and determine any association with sys-
temic inflammation and disease progression.
A retrospective study was conducted using thoracic CT imaging from 494 patients on the
AATD UK registry. Patients were categorised according to radiological and clinical outcome,
and comparisons made with respect to baseline demographics, lung function and high-
sensitivity CRP (hs-CRP).
Sixty-four patients (13%) had a nodule present on baseline imaging, and in total 132 patients
(27%) had a nodule on at least one scan, of which 2 were malignant. The presence of a lung
nodule was associated with significantly lower baseline percent predicted forced expiratory
volume in 1 s (FEV1 % predicted) (p Z 0.037) and percent predicted transfer coefficient of
the lung for carbon monoxide (Kco % predicted, p Z 0.001). Patients with self-resolving nod-
ules had higher baseline hs-CRP concentrations (p < 0.01) and more rapid decline in Kco
(p Z 0.03) compared to patients in whom no nodules were observed.
The prevalence of ‘incidental’ pulmonary nodules on CT imaging in patients with AATD was
13%. Self-resolving pulmonary nodules were associated with increased systemic inflammation
and progression of emphysema and may therefore reflect an important component of emphy-
sema pathogenesis or a marker of emphysema.
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respect to baseline demographics, baseline lung function,Solitary pulmonary nodules identified on thoracic CT im-
aging are defined as rounded opacities, smaller than 3 cm in
diameter and surrounded by lung parenchyma.1 Population-
based CT studies screening for lung cancer demonstrate
a prevalence ranging from 5 to 60%2 and they are also
a frequent finding in routine clinical imaging.3 Despite a low
risk of malignancy4 they require further investigation, and
interval CT scanning is advised by the Fleischner Society5
for up to 2 years depending on features such as the size
of the lesion and clinical risk factors.
Alpha 1-antitrypsin deficiency (AATD) is a hereditary
COPD phenotype, associated with a predisposition to
developing early onset emphysema that is traditionally
believed to arise from the relatively unopposed action of
neutrophil elastase and increased neutrophilic inflamma-
tion.6 AATD-associated emphysema is predominantly pan-
acinar and distributed in the basal region of the lung, in
comparison to usual COPD where emphysema is classically
centrilobular and distributed in the apical region.7,8 The
frequency and clinical significance of pulmonary nodules in
patients with AATD is unknown, and consequently, we un-
dertook a retrospective study of CT imaging in patients with
AATD on the Antitrypsin Deficiency Assessment and Pro-
gramme for Treatment (ADAPT) UK registry.
The aim of the study was to determine both the preva-
lence and radiological outcomes of pulmonary nodules
identified on CT scanning in patients with AATD, to enable
comparison with published CT screening studies. In addi-
tion, we sought to assess whether the presence of non-
malignant nodules were associated with increased systemic
inflammation and disease progression.Materials and methods
Study subjects
Subjects with the PiZ phenotype and who had at least one
thoracic CT scan at our centre between November 1996 and
September 2009 were selected for this retrospective study.
All patients had given written informed consent and the
programme was approved by the South Birmingham
Research and Ethics Committee. Alpha 1-antitrypsin level
and phenotype were verified by immunoassay and isoelec-
tric focussing, respectively, using a dried finger prick blood
spot (Heredilab; Salt Lake City, UT).
Study design
Clinical records, including radiology reports and, where
applicable, histopathology results, were reviewed for all
subjects. Initially patients were classified into a ‘nodule
present’ group, if a nodule was recorded in any scan, and
‘nodule absent’ group if no nodules were detected from all
CT imaging. Patients were subsequently classified into the
following four groups according to radiological and clinical
outcome: A resolved/resolving nodule, B-unchanged nod-
ule, C-malignant nodule and D-no nodule on at least 3 CT
scans.Comparisons between the groups were performed with
decline in forced expiratory volume in 1 s (FEV1) and
transfer coefficient of the lung for carbon monoxide (Kco),
and plasma high-sensitivity CRP (hs-CRP). Mean hs-CRP
comparisons were made before and after the exclusion of
those patients with known coexisting inflammatory disease
(e.g. rheumatoid arthritis) and those experiencing an
exacerbation within 6 weeks of blood sampling.
The proportion of subjects with a history of a resolved/
resolving nodule (group A) was compared in patients with
‘no FEV1 decline’ over the study period (0 ml/year) and
a ‘fast FEV1 decline’ group (decline  100 ml/year). Sim-
ilarly, a comparison was performed between a ‘no Kco
decline’ group (0 mmol/min/L/year) and ‘fast Kco
decline’ group (decline  0.06 mmol/min/L/year).
Methods
Patients were scanned at full inspiration without the use of
intravascular contrast, as previously described.7,9 Further
imaging was performed in those patients with a lung nodule
at the discretion of the clinican or multi-disciplinary team
according to clinical need. 18Fluorodeoxyglucose Positron
Emission TomograpyeComputed Tomograpy (18FDG PET-CT)
was performed with a General Electric Discovery STE PET-
CT scanner (incorporating a Lightspeed 8-slice CT scanner)
in one patient as part of another study but in whom an
unsuspected nodule was also seen during the investigation
and, in a further two patients, where diagnostic uncer-
tainty existed. All imaging was assessed by a single thoracic
radiologist and the presence of non-calcified pulmonary
nodules, rounded pulmonary opacification or nodular in-
filtrates were recorded. Additional data on nodule size and
smoking history were obtained from radiology reports and
clinical records.
Post-bronchodilator spirometry (CareFusion; San Diego,
CA) and carbon monoxide gas transfer (either on Bench-
mark; P.K. Morgan; Kent, UK or Jaeger Master Screen PFT;
CareFusion; San Diego, CA) were measured according to the
Association of Respiratory Technicians and Physiologists/
British Thoracic Society) guidelines.10 A minimum of 3
measurements over at least 3 years were used to determine
decline in FEV1 and Kco by linear regression. Normal values
for FEV1 and Kco were derived from the European Com-
munity for Coal and Steel normal regression equations11 and
Cotes equation respectively.12
Plasma sampling for high-sensitivity C-reactive protein
(hs-CRP) measurements were available in a subset of pa-
tients, and concentrations were determined using a com-
mercial enzyme-linked immunosorbent assay (Quantikine;
R&D Systems Inc; Minneapolis, MN).
Statistical analysis
Data analysis was performed using the Statistical Package
for the Social Sciences (SPSS) version 17.0 (SPSS Inc.; Chi-
cago, IL), with statistical significance defined as a p val-
ue  0.05. The Chi-square test was used to compare
proportions between groups, the Student’s t test for
continuous normally distributed variables and the
Lung nodules in alpha 1-antitrypsin deficiency 865ManneWhitney U test for nonparametric analysis. Receiver
operating characteristic (ROC) curve analysis was per-
formed to determine the predictive value for hs-CRP to
recognise nodules which subsequently resolved. Pearson
correlations were undertaken to compare continuous
variables.
Results
CT imaging was performed on 494 patients and, out of
a total of 1280 scans, a nodule was identified in 269 (21%).
Sixty-four patients (13%) had a nodule present on the
baseline imaging, and in total 132 patients (27%) were
noted to have a nodule on at least one CT scan. Patient
characteristics at baseline according to the presence or
absence of a nodule are shown in Table 1. Pulmonary
nodules were more frequently observed in smokers and ex-
smoker compared to never-smokers (p Z 0.014). The
presence of a nodule was associated lower baseline percent
predicted FEV1 (p Z 0.037) and percent predicted Kco
(p Z 0.001).
Sixty-one percent of patients with a nodule (n Z 80)
were assigned to group A (resolved or resolving nodules, see
Fig. 1), and a further 27% (n Z 36) to group B (stable
radiological appearance). In the 2 patients in group C, the
nodules were shown to be malignant on histopathology of
tissue biopsies (1-bronchial adenocarcinoma, 1-non-hodg-
kin’s lymphoma). Nodule size was greater than 5 mm in 54
patients, including the 2 patients with malignant disease.
The 14 patients who were found to have a nodule and
subsequently withdrew from the programme, were advised
to undergo follow up imaging at a local centre In group D,
no nodules were detected at any time in 95 patients who
had undergone at least 3 scans.
Comparison between groups A and D (see Table 2)
showed that there were no statistically significant differ-
ences with respect to age (p Z 0.135), smoking history
(p Z 0.108), baseline FEV1 (p Z 0.180), FEV1 decline
(p Z 0.851) or Kco decline (p Z 0.355). However, group A
had significantly lower baseline Kco (pZ 0.012) and higher
hs-CRP concentration (pZ 0.004; see Fig. 2) than group D.
No significant differences were observed between the
proportion of patients with a history of a resolved/resolving
nodule (i.e. from group A) in the ‘fast FEV1 decline’ groupTable 1 Comparison of patient characteristics and lung physio
groups (n Z 494).
Nodule present
Number (% of total) 132 (27)
Number of Males (%) 90 (68)
Age, years 52.0 (9.8)
Smoker or Ex-smoker, % 84.0
Pack year historya 19.8 (12.5e27.9
Baseline FEV1, L
a 1.37 (0.98e1.81
Baseline FEV1, % predicted
a 42.4 (32.7e57.2
Baseline Kco, mmol/min/kPa/L 0.96 (0.33)
Baseline Kco, % predicted 61.2 (19.93)
Data are presented as mean (SD) unless highlighted. The asterisk ind
a Expressed as median (interquartile range).(n Z 52) and the ‘slow FEV1 decline’ group (n Z 51; 19.6%
versus 15.4% respectively; pZ 0.573). There was a greater
proportion of patients from group A in the ‘fast Kco decline’
group (n Z 54) when compared with the group with ‘slow
Kco decline’ (n Z 57; 35.2% versus 17.5% respectively;
p Z 0.034). A significant correlation between hs-CRP con-
centration and Kco decline was observed (n Z 191,
r Z 0.147, p Z 0.04).
Positron Emission Tomography-CT (PET-CT) imaging was
performed in 3 patients, and in each case the nodules were
shown to be metabolically active, although resolution
occurred without therapeutic intervention.
Fig. 3 depicts the ROC curve for hs-CRP in predicting
which nodules subsequently resolved. Hs-CRP data was
available in 230 patients and included 50 cases of a resolved
or resolving nodule. The area under the curve was 0.619
(95% confidence intervals, 0.533e0.705; p Z 0.01).
Discussion
This retrospective study has shown that pulmonary nodules
are commonly observed in patients with AATD, and that the
majority of these are non-malignant. In many patients the
nodules remained static with time but patients with
a resolving nodule on serial CT imaging were those with
more severe lung disease, higher plasma hs-CRP concen-
tration and an accelerated physiological progression, when
assessed by decline in gas transfer.
CT-based screening studies for lung cancer have pro-
vided data on the prevalence of pulmonary nodules and
malignant lesions in asymptomatic subjects4,13 but there
have been no previous studies which have reported the
prevalence of pulmonary nodules in patients with usual
COPD or, as in the current cohort, in subjects with AATD.
The Early Lung Cancer Action Project14 included 1000
asymptomatic smokers or ex-smokers, above the age of 60
and with at least a 10 pack year smoking history. Twenty
three percent of subjects were found to have a non-
calcified nodule after baseline screening, which was com-
parable to the results from a recent Canadian Study.15 A
lower nodule frequency of 5% has been reported in a fur-
ther study, in which 54% of subjects were never-smokers.16
Collectively, these data suggest an association between the
presence of lung nodules and smoking, a finding which waslogy at baseline in the ‘nodule absent’ and ‘nodule present’
Nodule absent p Value
362 (73)
211 (58) 0.046*
50.0 (10.4) 0.066
72.7 0.014*
) 19.8 (10.0e27.0) 0.373
) 1.48 (1.00e2.27) 0.131
) 49.1 (33.0e70.7) 0.037*
1.10 (0.39) 0.007*
67.5 (2.39) 0.001*
icates significant difference between groups.
Figure 1 Flow diagram showing the outcomes of nodules in AATD patients undergoing thoracic CT scanning. Data are presented
as n (% of scanned patients); [% of patients with a nodule present].
866 D.R. Subramanian et al.also observed in the study reported here. In comparison to
the screening studies mentioned, our population had
a lower mean age and included 22% of never-smokers and,
consequently, represented a group with a lower risk of
malignancy. Neverthless, the incidence of non-calicified
nodules at baseline imaging was 13% and, overall, 27% of
subjects had a nodule on at least 1 scan, which represented
a significant proportion of patients who conventionally
required additional investigations.
In our cohort, a nodule subsequently proven to be ma-
lignant was found in only 2 patients and, in both cases,
a high clinical suspicion was evident from the initial scan,
based on a spiculated appearance that was not evident on
non-malignant nodules. In one further patient, an increase
in nodule size occurred over 4 months raising the suspicion
of malignancy, although subsequent investigations (that
included thoracotomy) found no evidence of malignancy.
Thus in keeping with previous studies14,17 we observed
a low malignacy rate. Recommendations of the Fleischner
Society advise confirmation of nodule stability on serial
imaging over at least a 2 year period before categorising
the nodule as benign, with some investigators advocatingTable 2 Comparison of patient characteristics and lung physiolo
at least 3 scans).
Group A
Number 80
Males (%) 59 (74)
Age, years 51.7 (9.3)
Smokers or Ex-smoker (%) 84.0
Pack year historya 20.4 (11.6e2
Baseline FEV1, L
a 1.36 (0.97e1
Baseline FEV1, % predicted
a 41.2 (31.6e5
Baseline Kco, mmol/min/kPa/L 0.95 (0.31)
Baseline Kco, % predicted 60.6 (19.1)
FEV1 decline, ml/year 48.8 (53.4)
Kco decline, mmol/min/kPa/L/year 0.036 (0.042)
Data are presented as mean (SD) unless highlighted. The asterisk ind
a Expressed as median (interquartile range).an even longer period of follow up.18 The increased cost to
health care services, patient anxiety, and the additional
radiation exposure (which may itself lead to an increased
risk of cancer19) are factors which have led some authors to
express concerns regarding the benefits of repeatedly im-
aging indeterminate small nodules, whilst the reported risk
of malignancy is low.20,21 Alternatively, others favour the
early use of videothoracoscopic surgery in patients with
good respiratory function22,23 to achieve a definitive diag-
nosis, and thereby avoiding serial imaging.
The current study did not identify any further malig-
nancies through the use of serial CT imaging and clinical
follow up. This suggests not only that such lesions are
common but that the application of Fleischner Society
recommendations for serial scans or surgical removal of
smooth nodules is likely to be unnecessary in the current
patient group, especially in subjects of a young age or
never-smokers. Detailed radiological characterisation was
not performed in this study, however, features reported to
favour a benign lesion include calcification within the
nodule, a smooth edge contour (as in all but 2 of our
observed nodules) and a lack of enhancement following thegy in groups A (resolved/resolving nodule) and D (no nodule in
Group D p Value
95
60 (63) 0.135
49.9 (8.5) 0.216
73.7 0.108
9.0) 23.0 (13.5e29.5) 0.475
.81) 1.54 (1.06e2.18) 0.180
5.9) 46.6 (32.5e69.7) 0.118
1.09 (0.38) 0.012*
67.8 (21.8) 0.032*
50.5 (57.5) 0.851
0.030 (0.034) 0.355
icates significant difference between groups.
Figure 2 Box plot of hs-CRP levels between patients in
groups A, B and D. Before (shaded) and after (unshaded)
exclusion of patients with a recent exacerbation or coexisting
inflammatory disease. The outer edges of the box plot are 25%
and 75% points, the solid line is the median and bars indicate
the 1.5-fold of the whole box length, p values shown for the
comparison between groups (ManneWhitney U test).
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lobulated26 contours are more suggestive of a malignancy,
as seen in the 2 patients in our study. However, in patients
with emphysema, it can be more difficult to distinguish
between benign and malignant lesions based solely on CT
appearance.27 Predictive models using multiple radiological
and clinical features have been shown to improve the
diagnostic accuracy even of experienced radiologists25,28
and may represent a potential tool for routine clinical
practice. The specificity for predicting malignancy inFigure 3 Diagnostic testing of the predictive value of hs-CRP
for a resolving nodule by ROC curve.lesions greater than 7 mm on CT can be increased from 41%
to 89%29 through the supplemental use of PET-CT which
therefore has a role some management algorithms.30
However, even this approach can be misleading as dem-
onstrated in the current study where 18FDG uptake was
assessed and shown to be increased in three subjects with
a pulmonary nodule, suggestive of malignancy, even though
the nodule subsequently resolved in each case.
Whilst the current and previous data indicate that the
vast majority of incidental nodules are non-malignant, the
cellular composition and clinical significance of these
nodules is largely unknown. In studies that have explored
nodule causation in unselected populations, it has been
shown that 80% are infectious granulomas,31,32 10%
hamartomas and the remaining 10% are caused by a vari-
ety of rarer disorders including non-infectious granulomas
and other benign tumours.33,34 However, it has been pro-
posed that the nodular changes seen on imaging in
smokers could be the precursor of emphysema. Remy-
Jardin et al.35 conducted a longitudinal study of 111 vol-
unteers, including 57 persistent smokers. Micronodular
abnormalities were present in 19 persistent smokers at
baseline imaging, and in 14 cases they increased or were
unchanged during the course of the study. In five cases
nodules had been replaced by emphysema and, con-
sequently, it was hypothesised that this sequential change
may reflect a causal link between localised inflammation
and the development of emphysema. In our cohort,
resolving lung nodules were more prevalent in patients
with evidence of accelerated disease progression, based
on contemporaneous Kco decline; however, although Kco
and CT densitometry correlate cross-sectionally36 it was
not possible to assess objectively whether there was an
association between nodule formation and the subsequent
parenchymal destruction as the subsequent scans were
performed in a limited and diagnostic manner over a short
period and hence were not suitable for quantitative
assessment.
Nevertheless, the current study found that all three
of the non-malignant-pulmonary nodules which were
assessed using PET-CT, showed increased 18FDG uptake,
which is suggestive of pulmonary neutrophilic inflamma-
tion37 underlying the pathophysiology of these lesions.
Consequently, it is possible that nodule formation may be
driven by neutrophilic inflammation and the natural history
of nodule resolution is the development of emphysema as
proposed in the study of Remy-Jardin et al.35
In the current study, the observation that hs-CRP con-
centration was higher in patients with transient lung nod-
ules supports an inflammatory process and indicates that
these patients have greater levels of systemic inflammation
and an association between systemic inflammation and the
formation of these resolving but ‘benign’ nodules. Howev-
er, cross-sectional COPD studies have shown that CRP
concentrations are inversely related to lung function,38 and
our finding of an elevated hs-CRP concentration in group A
may, therefore, be a reflection of the greater physiological
impairment seen in this group. Despite the aforementioned
association, the measurement of hs-CRP concentrations in
the AATD population was not shown to be a specific clinical
marker for the prediction of a resolving nodule and, there is
no data to support its’ role in monitoring nodule activity
868 D.R. Subramanian et al.other than in general. However, the observation that hs-
CRP concentration correlates with Kco decline indicates
a possible link between systemic inflammation and alveolar
destruction. It would be therefore be of interest to deter-
mine whether this association is replicated in patients
with usual COPD particularly with an emphysematous
phenotype.
One of the limitations of the current study was that the
research scanning protocol used for densitometry from the
start of the ADAPT programme in 1996, when quantitative
CT was in its’ infancy, was not the method of choice for
the imaging of nodules for clinical monitoring, It was
therefore not possible using this scanning protocol to
determine emphysema progression using CT lung densi-
tometry, which is now recognised to be a more sensitive
and specific method for the assessment of emphysema
progression than physiology.39e41 The consistent use of
a volumetric protocol, which was subsequently adopted in
preference to the original high-resolution protocol, would
also have allowed additional factors such as nodule vol-
ume and regional changes in lung density to be deter-
mined more clearly, and would be a useful adjunct for
future prospective studies. However the gas transfer cor-
rected for alveolar volume (Kco), which is still a good
marker of emphysema and its’ progression albeit less
sensitive than densitometry,42 does show a correlation
with nodule characteristics suggesting the 2 are related
perhaps with a common inflammatory background. The
incidence of lung cancer was low in the current study and
the true incidence may only be confirmed or determined
by pooling data from multiple AATD databases. Fur-
thermore, as this was a retrospective study there was
incomplete data for measurements such as hs-CRP con-
centration which was only performed in 230 of the 494
patients. Thus although a relationship to the nature of the
nodule was observed this should be confirmed with a fur-
ther prospective study.
In conclusion, the prevalence of nodules detected on
CT scanning in patients with AATD in our study was 13%. In
the few cases where malignancy was confirmed, the initial
nodule had a spiculated appearance not seen in the
others. Serial CT imaging of patients with incidental lung
nodules did not identify the development of malignant
change and therefore extended monitoring in nodules with
a smooth outline is likely to be unnecessary. Nodules that
underwent spontaneous resolution appeared to be asso-
ciated with a systemic inflammatory response and accel-
erated decline in gas transfer, suggesting a link between
inflammation, nodule formation and the progression of
emphysema.
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